NASDAQ:ACRX - AcelRx Pharmaceuticals Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $2.97 +0.07 (+2.41 %) (As of 07/19/2018 11:43 AM ET)Previous Close$2.90Today's Range$2.90 - $2.9752-Week Range$1.55 - $5.75Volume3,907 shsAverage Volume870,167 shsMarket Capitalization$153.96 millionP/E Ratio-2.64Dividend YieldN/ABeta2.4 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California. Receive ACRX News and Ratings via Email Sign-up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:ACRX CUSIPN/A Webwww.acelrx.com Phone650-216-3500 Debt Debt-to-Equity Ratio-0.20 Current Ratio4.05 Quick Ratio4.00 Price-To-Earnings Trailing P/E Ratio-2.64 Forward P/E Ratio-3.76 P/E GrowthN/A Sales & Book Value Annual Sales$7.99 million Price / Sales19.08 Cash FlowN/A Price / CashN/A Book Value($0.73) per share Price / Book-4.07 Profitability EPS (Most Recent Fiscal Year)($1.10) Net Income$-51,500,000.00 Net Margins-909.33% Return on EquityN/A Return on Assets-62.92% Miscellaneous Employees41 Outstanding Shares51,320,000Market Cap$153.96 AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions What is AcelRx Pharmaceuticals' stock symbol? AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX." How were AcelRx Pharmaceuticals' earnings last quarter? AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) released its quarterly earnings results on Wednesday, May, 9th. The specialty pharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.01. The specialty pharmaceutical company had revenue of $0.34 million for the quarter, compared to analyst estimates of $0.78 million. View AcelRx Pharmaceuticals' Earnings History. What price target have analysts set for ACRX? 9 brokerages have issued 1-year target prices for AcelRx Pharmaceuticals' stock. Their predictions range from $2.00 to $8.00. On average, they expect AcelRx Pharmaceuticals' stock price to reach $5.20 in the next year. This suggests a possible upside of 75.1% from the stock's current price. View Analyst Ratings for AcelRx Pharmaceuticals. What is the consensus analysts' recommendation for AcelRx Pharmaceuticals? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of AcelRx Pharmaceuticals' key competitors? Some companies that are related to AcelRx Pharmaceuticals include Five Prime Therapeutics (FPRX), Theratechnologies (THERF), Progenics Pharmaceuticals (PGNX), TIGENIX/S (TIG), Viking Therapeutics (VKTX), Akebia Therapeutics (AKBA), Prothena (PRTA), Insys Therapeutics (INSY), Obseva (OBSV), Beyondspring (BYSI), Merus (MRUS), CannTrust (CNTTF), Keryx Biopharmaceuticals (KERX), Aduro BioTech (ADRO) and Evolus (EOLS). Who are AcelRx Pharmaceuticals' key executives? AcelRx Pharmaceuticals' management team includes the folowing people: Dr. Pamela Pierce Palmer, Co-Founder, Chief Medical Officer & Director (Age 55)Ms. Jane Wright-Mitchell, Chief Legal Officer (Age 49)Mr. Lawrence G. Hamel, Chief Devel. Officer (Age 66)Mr. Anil N. Dasu, Chief Engineering Officer (Age 55)Mr. Vincent J. Angotti, CEO & Director (Age 50) Has AcelRx Pharmaceuticals been receiving favorable news coverage? News headlines about ACRX stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AcelRx Pharmaceuticals earned a media sentiment score of 0.06 on Accern's scale. They also gave media coverage about the specialty pharmaceutical company an impact score of 45.67 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. Who are AcelRx Pharmaceuticals' major shareholders? AcelRx Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include LEERINK REVELATION HEALTHCARE FUND I, L.P. (7.30%) and INDUSTRY VENTURES SECONDARY VIII, L.P. (7.30%). Company insiders that own AcelRx Pharmaceuticals stock include Lawrence G Hamel, Life Sciences Maste Perceptive, Mark G Edwards, Pamela P Palmer, Perceptive Advisors Llc, Raffi Asadorian and Vincent J Angotti. View Institutional Ownership Trends for AcelRx Pharmaceuticals. How do I buy shares of AcelRx Pharmaceuticals? Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is AcelRx Pharmaceuticals' stock price today? One share of ACRX stock can currently be purchased for approximately $2.97. How big of a company is AcelRx Pharmaceuticals? AcelRx Pharmaceuticals has a market capitalization of $153.96 million and generates $7.99 million in revenue each year. The specialty pharmaceutical company earns $-51,500,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. AcelRx Pharmaceuticals employs 41 workers across the globe. How can I contact AcelRx Pharmaceuticals? AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected] MarketBeat Community Rating for AcelRx Pharmaceuticals (NASDAQ ACRX)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 306 (Vote Outperform)Underperform Votes: 238 (Vote Underperform)Total Votes: 544MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/19/2018 by MarketBeat.com StaffFeatured Article: Should I follow buy, hold and sell recommendations?